Gilead Completes $7.8 Billion Arcellx Acquisition Deal
Gilead Sciences has finalized its acquisition of Arcellx, completing a deal valued at approximately $7.8 billion. The transaction marks a strategic expansion of Gilead’s oncology…
Read More...
Read More...
